Merck's Bet on Cancer Immunotherapy Is Paying Off in Spades and Helping Lung Cancer Patients Live Longer

New study results released Monday continue to cement drug giant Merck’s status as the force to be reckoned with in the lung cancer treatment space. Merck’s flagship cancer immunotherapy Keytruda (or pembrolizumab), combined with chemotherapy, helped ...